欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号AT/H/0920/001
药品名称Abacavir/Lamivudin Mylan Pharma 600mg/300mg Filmtabletten
活性成分
    • Abacavir sulfate 600.0 mg
    • Lamivudine 300.0 mg
剂型Film-coated tablet
上市许可持有人Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Irland RMS change from UK/H/6260/001
参考成员国 - 产品名称Austria (AT)
互认成员国 - 产品名称
    • United Kingdom (Northern Ireland) (XI)
    • Germany (DE)
      Abacavir/Lamivudin Vale 600 mg/300 mg Filmtabletten
    • Denmark (DK)
      Abacavir Lamivudin Vale
    • Belgium (BE)
      Abacavir/Lamivudine Mylan Pharma 600 mg/300 mg filmomhulde tabletten
    • Netherlands (NL)
    • Luxembourg (LU)
    • Ireland (IE)
    • France (FR)
    • Spain (ES)
    • Portugal (PT)
    • Greece (GR)
      ABACAVIR+LAMIVUDINE/VALE
    • Sweden (SE)
    • Norway (NO)
      Abakavir/Lamivudin/Vale
    • Finland (FI)
    • Latvia (LV)
      Abacavir/Lamivudine Mylan Pharma 600 mg/300 mg apvalkotās tabletes
    • Lithuania (LT)
      Abakaviras/Lamivudinas Vale 600 mg/300 mg plėvele dengtos tabletės
    • Estonia (EE)
      ABACAVIR/LAMIVUDINE MYLAN PHARMA
    • Bulgaria (BG)
      Abacavir Lamivudine Vale
    • Romania (RO)
      Abacavir/Lamivudină Viatris 600 mg/300 mg comprimate filmate
许可日期2017/09/02
最近更新日期2025/01/08
药物ATC编码
    • J05AR02 lamivudine and abacavir
申请类型
  • TypeLevel1:[not specified]
  • TypeLevel2:[not specified]
  • TypeLevel3:[not specified]
  • TypeLevel4:[not specified]
  • TypeLevel5:[not specified]
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase